SCHEMBL194096

SCHEMBL194096

Clc1cc(Cl)c(Cl)nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29549708 1.00 — —
SCHEMBL10321593 0.71 — —
SCHEMBL31425702 0.71 — —
SCHEMBL31465413 0.71 — —
SCHEMBL14074055 0.71 — —
SCHEMBL23932248 0.71 — —
SCHEMBL11255439 0.71 — —
SCHEMBL2936869 0.71 — —
SCHEMBL2646498 0.71 — —
SCHEMBL30930706 0.71 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 663 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118005615-A Pyridazine compound and preparation method, pharmaceutical composition and application thereof 中国药科大学 2024-05-10 — — CN claimed
CN-113698355-B Synthesis method of 4, 5-dihydroxypyridazine 郑州华赞医药科技有限公司 2023-05-26 — — CN claimed
CN-113698355-A Synthesis method of 4, 5-dihydroxypyridazine 郑州华赞医药科技有限公司 2021-11-26 — — CN claimed
US-12637468-B2 Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators Shanghai Simr Biotechnology Co., Ltd. (CN) 2026-05-26 — — US disclosed
WO-2026090330-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 — — WO disclosed
WO-2026090411-A1 BRM AND BRG1 TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE PRELUDE THERAPEUTICS INCORPORATED (US) 2026-04-30 — — WO disclosed
EP-4727944-A1 [1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES USEFUL AS A MEDICAMENT Perha Pharmaceuticals (FR) 2026-04-22 — — EP disclosed
EP-4129986-B1 SUBSTITUTED PYRIDAZINE COMPOUND TENVIE THERAPEUTICS INC (US) 2026-03-11 — — EP disclosed
US-12569485-B2 SMARCA inhibitors and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-03-10 — — US disclosed
US-20260055065-A1 PYRIDAZINONE COMPOUNDS WHICH MODULATE MUTANT PROTEINS FOR TREATING RESPIRATORY DISEASES HOSPITAL FOR SICK CHILDREN (CA) 2026-02-26 — — US disclosed
EP-4692090-A1 TRICYCLIC COMPOUND AS ATR KINASE INHIBITOR Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (CN) 2026-02-11 — — EP disclosed
US-6391883-B1 INSECTICIDES SYNGENTA LIMITED (GB) 2002-05-21 — — US disclosed
EP-1195378-A1 Pyridotriazines and pyridopyridazines WARNER-LAMBERT COMPANY (US) 2002-04-10 — — EP disclosed
US-6207676-B1 Bicyclic amines ZENECA LIMITED (GB) 2001-03-27 — — US disclosed
EP-0828739-A1 BICYCLIC AMINES AS INSECTICIDES ZENECA LIMITED (GB) 1998-03-18 — — EP disclosed
WO-1996037494-A1 BICYCLIC AMINES AS INSECTICIDES ZENECA LIMITED (GB) 1996-11-28 — — WO disclosed
EP-0372305-B1 PIPERAZINYLALKYL-3(2H)-PYRIDAZINONES, METHOD FOR THEIR PREPARATION AND THEIR USE AS ANTIHYPERTENSIVE AGENTS Hafslund Nycomed Pharma Aktiengesellschaft (AT) 1993-08-04 — — EP disclosed
US-5034391-A Piperazinylalkyl-3(2H)-pyridazinones and the use thereof as agents lowering blood pressure CL PHARMA AKTIENGESELLSCHAFT (AT) 1991-07-23 — — US disclosed
EP-0372305-A1 Piperazinylalkyl-3(2H)-pyridazinones, method for their preparation and their use as antihypertensive agents Hafslund Nycomed Pharma Aktiengesellschaft (AT) 1990-06-13 — — EP disclosed
US-3978057-A HYPOTENSIVE AGENTS SANDOZ, INC. (US) 1976-08-31 — — US disclosed
Send feedback